Why the study?
Do patients with HFpEF have increased cardiac hypertrophy, epicardial CAD, coronary microvascular rarefaction, and myocardial fibrosis compared to controls?
Do patients with HFpEF have increased cardiac hypertrophy, epicardial CAD, coronary microvascular rarefaction, and myocardial fibrosis compared to controls?
HFpEF is associated with increased cardiac hypertrophy, epicardial CAD, coronary microvascular rarefaction, and myocardial fibrosis, which may contribute to the characteristic diastolic dysfunction.
Supports microvascular and anti-fibrotic investigation in HFpEF; leaves open causality and therapeutic modification.
In this study, patients with HFpEF had more cardiac hypertrophy, epicardial CAD, coronary microvascular rarefaction, and myocardial fibrosis than controls. Each of these findings may contribute to the left ventricular diastolic dysfunction and cardiac reserve function impairment characteristic of HFpEF.
No takes yet. Share an insight, caveat, or question.
Mohammed et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: